Bicyclic GABAA α5 Modulators for Selective Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for compounds that can selectively modulate the GABAA α5 receptor to treat or prevent diseases related to it, as existing modulators often cause undesired CNS side effects due to non-selectivity.
Innovation Solution
Development of compounds of formula (I) with high affinity and selectivity for the GABAA α5 receptor, acting as negative allosteric modulators to treat or prevent diseases related to the GABAA α5 receptor, including pharmaceutical compositions and combinations with other active ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective GABAA receptor modulators are used, then broad therapeutic effects are achieved, but undesired CNS side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (cyclic substituents at positions 1 and 5, specific R1-R7 groups) that confer selective affinity for the GABAA α5 receptor subtype. This structural specificity enables the compound to target only the desired receptor subtype, producing therapeutic effects without activating other GABAA receptor subtypes that would cause CNS side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize receptor selectivity. By adjusting these chemical parameters, the compound achieves high affinity for GABAA α5 while maintaining low affinity for other GABAA receptor subtypes, thereby resolving the contradiction between therapeutic efficacy and side effect profile.
2Object-affected harmful factors
If selective GABAA α5 receptor modulators are developed, then CNS side effects are reduced, but compound specificity and affinity must be precisely optimized
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments with specific roles: the core bicyclic structure provides the basic pharmacophore, while cyclic substituents at positions 1 and 5 provide selectivity, and R1-R7 groups fine-tune affinity and pharmacokinetic properties. This modular segmentation allows systematic optimization of specificity without compromising overall compound stability.
Solution Approach 2:
The patent uses composite materials by combining multiple structural elements (bicyclic core, cyclic substituents, various R groups) into a composite molecular architecture. This composite structure integrates the functions of each component to achieve the desired balance of high affinity and high selectivity for GABAA α5, resolving the precision requirement through synergistic structural combination.
3Reliability
If high affinity compounds are designed, then therapeutic efficacy is improved, but selectivity for specific receptor subtypes may be compromised
Solution Approach 1:
The patent employs the intermediary principle by introducing specific cyclic substituents as mediating structures that facilitate selective interaction with GABAA α5 receptor. These cyclic groups act as intermediaries between the core pharmacophore and the receptor binding site, enabling high affinity binding while maintaining subtype selectivity through steric and electronic complementarity specific to the α5 receptor configuration.
Data Source
AI summary
The present invention provides compounds of formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.